Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction

A national wide assessment

Cho Kai Wu, Yin Tseng Huang, Jen Kuang Lee, Jyh Ming Jimmy Juang, Chia Ti Tsai, Ling Pin Lai, Juey Jen Hwang, Fu Tien Chiang, Jiunn Lee Lin, Pau Chung Chen, Lian Yu Lin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: Anti-anxiety medication in patients with anxiety may lessen the stress and thereby lower their risk for myocardial infarction (MI). The aim of current study is to examine an association between the use of anti-anxiety medication and long-term mortality risk in patients following MI. Methods: A universal national health insurance (NHI) program has been implemented in Taiwan since 1995. We used system sampling database from 1997 to 2008 with a total of 1,000,000 subjects. We included subjects with first episode of MI and were above 30 years old. Sudden death, cardiovascular mortality, and heart failure hospitalization were assessed in all included subjects. Anti-anxiety as well as other medications and risk factors were obtained. Cox regression analysis was used to evaluate the adjusted hazard ratio (HR) for all patients and subgroups. Results: The adjusted HRs of sudden death were significantly associated with increased benzodiazepam (BZD) dosage (HRs=0.639, 1.003, 1.957 from Q2 to Q4 vs. Q1, p=.019 for trend) during approximately 4.8 years. For cardiac mortality and heart failure hospitalization, there was a J-curve dose-response relationship. The HRs for cardiac mortality were 0.255 (p<.001) and 0.385 (p<.001) for Q2 and Q3 vs. Q1, respectively. For patients receiving higher doses of daily BZDs (>5mg), protective effects for cardiac mortality and heart failure hospitalization decreased and a J-curve dose-response relationship was seen. Conclusion: Anti-anxiety medications are independent associated with a decreased risk of cardiac mortality and heart failure hospitalization in patients after a new MI.

Original languageEnglish
Pages (from-to)496-502
Number of pages7
JournalAtherosclerosis
Volume235
Issue number2
DOIs
Publication statusPublished - Aug 1 2014
Externally publishedYes

Fingerprint

Anti-Anxiety Agents
Heart Failure
Myocardial Infarction
Anxiety
Mortality
Hospitalization
National Health Programs
Sudden Death
Taiwan
Regression Analysis
Databases

Keywords

  • Anti-anxiety
  • Cardiovascular
  • Myocardial infarction
  • Outcome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Wu, C. K., Huang, Y. T., Lee, J. K., Jimmy Juang, J. M., Tsai, C. T., Lai, L. P., ... Lin, L. Y. (2014). Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction: A national wide assessment. Atherosclerosis, 235(2), 496-502. https://doi.org/10.1016/j.atherosclerosis.2014.05.918

Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction : A national wide assessment. / Wu, Cho Kai; Huang, Yin Tseng; Lee, Jen Kuang; Jimmy Juang, Jyh Ming; Tsai, Chia Ti; Lai, Ling Pin; Hwang, Juey Jen; Chiang, Fu Tien; Lin, Jiunn Lee; Chen, Pau Chung; Lin, Lian Yu.

In: Atherosclerosis, Vol. 235, No. 2, 01.08.2014, p. 496-502.

Research output: Contribution to journalArticle

Wu, CK, Huang, YT, Lee, JK, Jimmy Juang, JM, Tsai, CT, Lai, LP, Hwang, JJ, Chiang, FT, Lin, JL, Chen, PC & Lin, LY 2014, 'Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction: A national wide assessment', Atherosclerosis, vol. 235, no. 2, pp. 496-502. https://doi.org/10.1016/j.atherosclerosis.2014.05.918
Wu, Cho Kai ; Huang, Yin Tseng ; Lee, Jen Kuang ; Jimmy Juang, Jyh Ming ; Tsai, Chia Ti ; Lai, Ling Pin ; Hwang, Juey Jen ; Chiang, Fu Tien ; Lin, Jiunn Lee ; Chen, Pau Chung ; Lin, Lian Yu. / Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction : A national wide assessment. In: Atherosclerosis. 2014 ; Vol. 235, No. 2. pp. 496-502.
@article{0bb26b72d6c64b93b661c5c2e575a2d6,
title = "Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction: A national wide assessment",
abstract = "Objective: Anti-anxiety medication in patients with anxiety may lessen the stress and thereby lower their risk for myocardial infarction (MI). The aim of current study is to examine an association between the use of anti-anxiety medication and long-term mortality risk in patients following MI. Methods: A universal national health insurance (NHI) program has been implemented in Taiwan since 1995. We used system sampling database from 1997 to 2008 with a total of 1,000,000 subjects. We included subjects with first episode of MI and were above 30 years old. Sudden death, cardiovascular mortality, and heart failure hospitalization were assessed in all included subjects. Anti-anxiety as well as other medications and risk factors were obtained. Cox regression analysis was used to evaluate the adjusted hazard ratio (HR) for all patients and subgroups. Results: The adjusted HRs of sudden death were significantly associated with increased benzodiazepam (BZD) dosage (HRs=0.639, 1.003, 1.957 from Q2 to Q4 vs. Q1, p=.019 for trend) during approximately 4.8 years. For cardiac mortality and heart failure hospitalization, there was a J-curve dose-response relationship. The HRs for cardiac mortality were 0.255 (p<.001) and 0.385 (p<.001) for Q2 and Q3 vs. Q1, respectively. For patients receiving higher doses of daily BZDs (>5mg), protective effects for cardiac mortality and heart failure hospitalization decreased and a J-curve dose-response relationship was seen. Conclusion: Anti-anxiety medications are independent associated with a decreased risk of cardiac mortality and heart failure hospitalization in patients after a new MI.",
keywords = "Anti-anxiety, Cardiovascular, Myocardial infarction, Outcome, Anti-anxiety, Cardiovascular, Myocardial infarction, Outcome",
author = "Wu, {Cho Kai} and Huang, {Yin Tseng} and Lee, {Jen Kuang} and {Jimmy Juang}, {Jyh Ming} and Tsai, {Chia Ti} and Lai, {Ling Pin} and Hwang, {Juey Jen} and Chiang, {Fu Tien} and Lin, {Jiunn Lee} and Chen, {Pau Chung} and Lin, {Lian Yu}",
year = "2014",
month = "8",
day = "1",
doi = "10.1016/j.atherosclerosis.2014.05.918",
language = "English",
volume = "235",
pages = "496--502",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction

T2 - A national wide assessment

AU - Wu, Cho Kai

AU - Huang, Yin Tseng

AU - Lee, Jen Kuang

AU - Jimmy Juang, Jyh Ming

AU - Tsai, Chia Ti

AU - Lai, Ling Pin

AU - Hwang, Juey Jen

AU - Chiang, Fu Tien

AU - Lin, Jiunn Lee

AU - Chen, Pau Chung

AU - Lin, Lian Yu

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Objective: Anti-anxiety medication in patients with anxiety may lessen the stress and thereby lower their risk for myocardial infarction (MI). The aim of current study is to examine an association between the use of anti-anxiety medication and long-term mortality risk in patients following MI. Methods: A universal national health insurance (NHI) program has been implemented in Taiwan since 1995. We used system sampling database from 1997 to 2008 with a total of 1,000,000 subjects. We included subjects with first episode of MI and were above 30 years old. Sudden death, cardiovascular mortality, and heart failure hospitalization were assessed in all included subjects. Anti-anxiety as well as other medications and risk factors were obtained. Cox regression analysis was used to evaluate the adjusted hazard ratio (HR) for all patients and subgroups. Results: The adjusted HRs of sudden death were significantly associated with increased benzodiazepam (BZD) dosage (HRs=0.639, 1.003, 1.957 from Q2 to Q4 vs. Q1, p=.019 for trend) during approximately 4.8 years. For cardiac mortality and heart failure hospitalization, there was a J-curve dose-response relationship. The HRs for cardiac mortality were 0.255 (p<.001) and 0.385 (p<.001) for Q2 and Q3 vs. Q1, respectively. For patients receiving higher doses of daily BZDs (>5mg), protective effects for cardiac mortality and heart failure hospitalization decreased and a J-curve dose-response relationship was seen. Conclusion: Anti-anxiety medications are independent associated with a decreased risk of cardiac mortality and heart failure hospitalization in patients after a new MI.

AB - Objective: Anti-anxiety medication in patients with anxiety may lessen the stress and thereby lower their risk for myocardial infarction (MI). The aim of current study is to examine an association between the use of anti-anxiety medication and long-term mortality risk in patients following MI. Methods: A universal national health insurance (NHI) program has been implemented in Taiwan since 1995. We used system sampling database from 1997 to 2008 with a total of 1,000,000 subjects. We included subjects with first episode of MI and were above 30 years old. Sudden death, cardiovascular mortality, and heart failure hospitalization were assessed in all included subjects. Anti-anxiety as well as other medications and risk factors were obtained. Cox regression analysis was used to evaluate the adjusted hazard ratio (HR) for all patients and subgroups. Results: The adjusted HRs of sudden death were significantly associated with increased benzodiazepam (BZD) dosage (HRs=0.639, 1.003, 1.957 from Q2 to Q4 vs. Q1, p=.019 for trend) during approximately 4.8 years. For cardiac mortality and heart failure hospitalization, there was a J-curve dose-response relationship. The HRs for cardiac mortality were 0.255 (p<.001) and 0.385 (p<.001) for Q2 and Q3 vs. Q1, respectively. For patients receiving higher doses of daily BZDs (>5mg), protective effects for cardiac mortality and heart failure hospitalization decreased and a J-curve dose-response relationship was seen. Conclusion: Anti-anxiety medications are independent associated with a decreased risk of cardiac mortality and heart failure hospitalization in patients after a new MI.

KW - Anti-anxiety

KW - Cardiovascular

KW - Myocardial infarction

KW - Outcome

KW - Anti-anxiety

KW - Cardiovascular

KW - Myocardial infarction

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=84921686107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921686107&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2014.05.918

DO - 10.1016/j.atherosclerosis.2014.05.918

M3 - Article

VL - 235

SP - 496

EP - 502

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -